Autolus Therapeutics plc (NASDAQ:AUTL) Shares Acquired by TFG Asset Management GP Ltd

TFG Asset Management GP Ltd grew its position in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 3.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,250,000 shares of the company’s stock after purchasing an additional 250,000 shares during the quarter. Autolus Therapeutics comprises approximately 4.2% of TFG Asset Management GP Ltd’s investment portfolio, making the stock its 5th largest position. TFG Asset Management GP Ltd owned approximately 3.10% of Autolus Therapeutics worth $19,388,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of AUTL. Jane Street Group LLC bought a new stake in shares of Autolus Therapeutics during the 4th quarter valued at about $26,000. Barclays PLC boosted its holdings in shares of Autolus Therapeutics by 1,094.3% during the 4th quarter. Barclays PLC now owns 11,859 shares of the company’s stock worth $28,000 after buying an additional 10,866 shares in the last quarter. Capstone Investment Advisors LLC bought a new position in shares of Autolus Therapeutics during the 3rd quarter worth approximately $51,000. Dumont & Blake Investment Advisors LLC acquired a new stake in shares of Autolus Therapeutics during the 4th quarter worth approximately $35,000. Finally, Arkadios Wealth Advisors bought a new stake in shares of Autolus Therapeutics in the 4th quarter valued at $47,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Trading Up 0.5 %

Autolus Therapeutics stock opened at $2.07 on Friday. The firm’s fifty day moving average price is $2.15 and its two-hundred day moving average price is $3.08. The firm has a market capitalization of $550.81 million, a price-to-earnings ratio of -1.71 and a beta of 2.07. Autolus Therapeutics plc has a 1-year low of $1.68 and a 1-year high of $6.63.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. The Goldman Sachs Group raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the stock from $7.00 to $7.60 in a research note on Monday, November 18th. Needham & Company LLC restated a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research note on Monday, January 13th. Finally, Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target on the stock in a research note on Friday, November 15th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $10.40.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.